FUTURENCT07257718
A Phase II, Prospective, Single-center Study of FAPI PET Imaging and Liquid Biopsy in Bladder Cancer
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date: Sep 2026 to Nov 2026 Show 5 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 207 words
- Interventions modified
- Secondary endpoint revised
- Study title shortened, about 5 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Assessing the diagnostic accuracy of FAPI PET and liquid biopsy in bladder cancer staging vs conventional imaging
Timeframe: 1 day
Secondary (1)
Assessing the disease burden of FAPI PET vs liquid biopsy in bladder cancer staging
Arms and interventions
BC patients eligible for radical cystectomyExperimental
BC patients treated with radical cystectomy ± neoadjuvant therapy
BC patients treated with systemic therapyExperimental
patients eligible for conservative treatment
Diagnostic tests: FAPI PET/CT with [68Ga]Ga-BED003, ctDNA/utDNA liquid biopsy